Artivion (AORT) Corporate presentation summary

Strategic focus and leadership

• Specializes in aortic disease with a portfolio spanning human tissue, mechanical valves, stent grafts, and surgical sealants.

• Leadership team brings decades of experience from major medtech firms, supporting innovation and execution.

Financial performance and growth

• FY25 revenue reached $444 million with $90 million EBITDA; FY26 revenue guidance is $480–496 million, up 7–11%.

• Sustained double-digit revenue growth and EBITDA growth at twice the revenue rate, driven by high-margin products and operating leverage.

• Adjusted EBITDA expected to grow 12–20% in FY26, reaching $100–107 million.

• Net debt leverage reduced from 6.7x in 2022 to 1.8x by March 2026, reflecting strong deleveraging.

Product innovation and clinical data

• On-X heart valve demonstrated 87% reduction in major bleeding and significant mortality benefit in patients ≤65 years.

• On-X market share reached 62% in FY25 with 21% year-over-year sales growth, accelerated by new clinical data.

• Stent graft business achieved 18% three-year CAGR, focusing on complex, less competitive segments with a $2B TAM.

• AMDS device showed strong clinical outcomes, lowering 30-day major adverse events to 27% vs. 58% for controls.

• Endospan NEXUS trial showed a 63% reduction in major adverse events at 30 days, with high survival and low morbidity at one year.